Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …

The interleukin 17 (IL-17) family of cytokines contains 6 structurally related cytokines, IL-17A
through IL-17F. IL-17A, the prototypical member of this family, just passed the 25 th …

Side Effects of Immune Checkpoint Blockade The wide range of immune-related adverse
effects associated with immune checkpoint blockade can complicate this effective therapy …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

The balance between Th17 cells and regulatory T cells (Tregs) has emerged as a prominent
factor in regulating autoimmunity and cancer. Th17 cells are vital for host defense against …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Background: Cancer immunotherapy with checkpoint inhibitors (CPIs) is associated with
frequent immune-related adverse events (irAEs) and is often not recommended for patients …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …